Silo pharma enters into letter of intent to form joint venture with hoth therapeutics to develop obesity treatment targeting $16 billion global market

Technology co-developed by the u.s. department of veterans affairs and emory university new york, june 25, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with hoth therapeutics, inc. (nasdaq: hoth) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology hoth has exclusively licensed from the u.s. department of veterans affairs (va) that was co-developed by the va and emory university. the novel therapeutic platform centers on glial cell line-derived neurotrophic factor (gdnf), a va-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
SILO Ratings Summary
SILO Quant Ranking